Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Have Never Been This Bullish On Genomic Health, Inc. (GHDX)

Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap stocks. There is little or no publicly-available information at all on some of these small companies, which makes it hard for an individual investor to pin down a winner within the small-cap space. However, hedge funds and other big asset managers can do the due diligence and analysis for you instead, thanks to their highly-skilled research teams and vast resources to conduct an appropriate evaluation process. Looking for potential winners within the small-cap galaxy of stocks? We believe following the smart money is a good starting point.

Is Genomic Health, Inc. (NASDAQ:GHDX) a bargain? The smart money is getting more bullish. The number of bullish hedge fund positions inched up by 1 lately. Our calculations also showed that GHDX isn’t among the 30 most popular stocks among hedge funds. GHDX was in 25 hedge funds’ portfolios at the end of March. There were 24 hedge funds in our database with GHDX positions at the end of the previous quarter.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the market by 40 percentage points since May 2014 through May 30, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that’ll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 30.9% through May 30, 2019. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

Felix Baker - Baker Bros.

We’re going to take a glance at the recent hedge fund action encompassing Genomic Health, Inc. (NASDAQ:GHDX).

How have hedgies been trading Genomic Health, Inc. (NASDAQ:GHDX)?

Heading into the second quarter of 2019, a total of 25 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 4% from the fourth quarter of 2018. On the other hand, there were a total of 15 hedge funds with a bullish position in GHDX a year ago. So, let’s review which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

GHDX_june2019

The largest stake in Genomic Health, Inc. (NASDAQ:GHDX) was held by Baker Bros. Advisors, which reported holding $714.4 million worth of stock at the end of March. It was followed by Renaissance Technologies with a $166.7 million position. Other investors bullish on the company included GLG Partners, Millennium Management, and AQR Capital Management.

Now, key hedge funds were leading the bulls’ herd. Laurion Capital Management, managed by Benjamin A. Smith, assembled the biggest position in Genomic Health, Inc. (NASDAQ:GHDX). Laurion Capital Management had $1.5 million invested in the company at the end of the quarter. Israel Englander’s Millennium Management also initiated a $0.7 million position during the quarter. The following funds were also among the new GHDX investors: Bruce Kovner’s Caxton Associates LP and George Zweig, Shane Haas and Ravi Chander’s Signition LP.

Let’s also examine hedge fund activity in other stocks – not necessarily in the same industry as Genomic Health, Inc. (NASDAQ:GHDX) but similarly valued. We will take a look at Quidel Corporation (NASDAQ:QDEL), Sunoco LP (NYSE:SUN), Colony Capital Inc (NYSE:CLNY), and Ligand Pharmaceuticals Inc. (NASDAQ:LGND). This group of stocks’ market valuations resemble GHDX’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
QDEL 18 119938 2
SUN 7 20219 0
CLNY 23 380794 -3
LGND 23 445210 -1
Average 17.75 241540 -0.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 17.75 hedge funds with bullish positions and the average amount invested in these stocks was $242 million. That figure was $1055 million in GHDX’s case. Colony Capital Inc (NYSE:CLNY) is the most popular stock in this table. On the other hand Sunoco LP (NYSE:SUN) is the least popular one with only 7 bullish hedge fund positions. Compared to these stocks Genomic Health, Inc. (NASDAQ:GHDX) is more popular among hedge funds. Our calculations showed that top 20 most popular stocks among hedge funds returned 1.9% in Q2 through May 30th and outperformed the S&P 500 ETF (SPY) by more than 3 percentage points. Unfortunately GHDX wasn’t nearly as popular as these 20 stocks and hedge funds that were betting on GHDX were disappointed as the stock returned -24.3% during the same period and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as 13 of these stocks already outperformed the market in Q2.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...